Placebo (Zenagamtide)
Sponsors
Novo Nordisk A/S
Conditions
Atherosclerotic cardiovascular disease and either overweight or obesityParticipants with type 2 diabetesParticipants with type 2 diabetes and chronic kidney disease
Phase 3
Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)
Not yet recruitingCTIS2026-525182-53-00
Target: 1520Updated: 2026-09-18
Efficacy and safety of zenagamtide s.c. once weekly compared to semaglutide s.c. once weekly at lower dose levels in participants with type 2 diabetes inadequately controlled on metformin, SGLT2i, or both (AMBITION 4)
Not yet recruitingCTIS2026-525474-20-00
Target: 70Updated: 2026-10-22
Efficacy and safety of zenagamtide s.c. once weekly compared to semaglutide s.c. once weekly at higher dose levels in participants with type 2 diabetes inadequately controlled on metformin, SGLT2i, or both (AMBITION 3)
Not yet recruitingCTIS2026-525472-26-00
Target: 220Updated: 2026-10-23
Efficacy and safety of zenagamtide s.c. once weekly compared to placebo in participants with type 2 diabetes inadequately controlled on diet and exercise (AMBITION 1)
Not yet recruitingCTIS2026-525470-18-00
Target: 35Updated: 2026-10-26
Efficacy and safety of zenagamtide s.c. once weekly compared to placebo in participants with type 2 diabetes and chronic kidney disease inadequately controlled on once daily basal insulin alone or in combination with metformin, SGLT2i, or both (AMBITION 2)
Not yet recruitingCTIS2026-525471-13-00
Target: 95Updated: 2026-10-28